Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

55 study records (showing up to 30 per record type)

• Registered trial NCT03518034 Phase 4 Completed (results not assessed here)
  A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
  Condition or outcome area: Hypogonadism|Cardiovascular Diseases
  2018-05-03 · Subject: Testosterone; SR-05000001542-1; Spectrum4_000114; AB00053134_04; KBioSS_001813; Spectrum2_001799; HMS2091C05; IDI1_000744; KBioGR_000468; Spectrum_001333 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00002189 Phase 2 Completed (results not assessed here)
  Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
  Condition or outcome area: Sarcoma, Kaposi|HIV Infections
  Subject: Taxol; Paclitaxel · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03472456 Completed (results not assessed here)
  Endodontic Medications for Irreversible Pulpitis: Articaine or Eugenol?
  Condition or outcome area: Pulpitides|Endodontic Inflammation|Toothaches|Operative Dentistry
  2018-03-22 · Subject: Eugenol; eugenol 4-Allyl-2-methoxyphenol; caryophyllic acid; EINECS 202-589-1; D0O4QB; Eugenol, tested according to Ph.Eur.; SCHEMBL20361; NCGC00091449-08; Eugenol, primary pharmaceutical reference standard; 1,3,4-Eugenol · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04998695 Completed (results not assessed here)
  Health Effects of Consuming Olive Pomace Oil
  Condition or outcome area: Healthy|Hypercholesterolemia
  2019-09-09 · Subject: You Gan Lan; 油橄榄; Common Olive; Olea Europaea · open the herb record · ClinicalTrials.gov
• Registered trial NCT04997122 Completed (results not assessed here)
  Health Effects of Consuming Olive Pomace Oil
  Condition or outcome area: Healthy|Hypercholesterolemia
  2018-04-02 · Subject: You Gan Lan; 油橄榄; Common Olive; Olea Europaea · open the herb record · ClinicalTrials.gov
• Registered trial NCT01141803 Completed (results not assessed here)
  Effect of Apple and Apple Pomace on Inflammation and Cholesterol Metabolism in Healthy Overweight
  Condition or outcome area: Cardiovascular Diseases
  2008-07 · Subject: Ping Guo; 苹果; Apple; Fructus Mali Pumilae · open the herb record · ClinicalTrials.gov
• Registered trial NCT02986165 Completed (results not assessed here)
  Effect of Ingesting a Tomato Pomace Extract on Platelet Aggregation
  Condition or outcome area: Cardiovascular Diseases
  2016-09 · Subject: Fan Qie; 番茄; Tomato; Fructus Lycopersici Esculenti · open the herb record · ClinicalTrials.gov
• Systematic review registration CRD42023470356 Registered protocol, no results here: Review Ongoing
  Magnesium sulfate enhances the effect of the peripheral analgesic cocktail in total knee arthroplasty: systematic review and meta-analysis of randomized controlled trials
  Condition or outcome area: Total knee arthroplasty (TKA) is an effective surgical intervention aimed at enhancing function and alleviating pain in patients with end-stage knee joint disorders. Effective postoperative pain management is crucial for early recovery and enhanced patient satisfaction. As a pivotal element within multimodal analgesia, peripheral analgesia techniques have been extensively used in TKA throughout the past decade. The standard pharmaceutical approach for peripheral analgesia typically involves comb
  2023-10-18 · Subject: Magnesium sulfate; Magnesium Sulfate; 7487-88-9; Magnesium sulphate; Magnesium sulfate anhydrous; MgSO4; Magnesium sulfate (1:1); Magnesiumsulfat; Sal Angalis; Sal De sedlitz · open the ingredient record
• Systematic review registration CRD42023393866 Registered protocol, no results here: Review Ongoing
  A meta-analytic review of pharmaceutical and non-pharmaceutical therapies for diaper dermatitis in infants
  Condition or outcome area: Diaper rash, Diaper dermatitis
  2023-03-30 · Subject: Zinc oxide; Zinc White; 1314-13-2; oxozinc; Zinc Oxide Powder; Chinese White; Snow white; Akro-zinc bar 85; MFCD00011300; Azo-33 · open the ingredient record
• Systematic review registration CRD42023393866 Registered protocol, no results here: Review Ongoing
  A meta-analytic review of pharmaceutical and non-pharmaceutical therapies for diaper dermatitis in infants
  Condition or outcome area: Diaper rash, Diaper dermatitis
  2023-03-30 · Subject: Lu Hui; 芦荟; Aloe; Aloes · open the herb record
• Systematic review registration CRD42022365657 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of acupuncture combined with Xuefu Zhuyu Decoction on major adverse cardiovascular events after percutaneous coronary intervention: A protocol for systematic review and meta-analysis
  Condition or outcome area: The occurrence of major adverse cardiovascular events (MACE) in the postoperative period has become one of the major factors affecting the long-term outcome of patients after PCI. Intensive treatment with conventional western drugs after PCI still has some shortcomings, such as side effects of drugs and expensive medical costs. The clinical efficacy of acupuncture combined with XFZYD after PCI is superior to that of conventional western drug therapy, but the strength of evidence from a single ra
  2022-10-19 · Subject: Xue Fu Zhu Yu Tang; 血府逐瘀汤; Xue Fu Zhu Yu Decoction · open the formula record
• Systematic review registration CRD42021268538 Registered protocol, no results here: Review Ongoing
  A traditional herbal formula, Tong Xie Yao Fang, for irritable bowel syndrome: a systematic review and meta-analysis
  Condition or outcome area: Irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain, discomfort, bloating, and alterations of defecation habits. It is estimated that the worldwide prevalence is 11.2%. Conventional recommendations for IBS usually include antidiarrheals, antidepressants, antispasmodics, bulking agents, osmotic laxatives. Many patients turn to traditional herbs for help as the current symptomatic treatments are not effective. Modern pharmaceutical studies show TXYF promotes mucosal repair.
  2021-08-24 · Subject: Tong Xie Yao Fang （ Yuan Ming ： Bai Zhu Shao Yao San ）; 痛泻要方; Tong Xie Yao Recipe · open the formula record
• Systematic review registration CRD42022314843 Registered protocol, no results here: Review Ongoing
  Comparative Efficacy of Chinese Patent Medicines for Early Diabetic Kidney Disease: A Systematic Review and Network Meta Analysis
  Condition or outcome area: diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes mellitus (DM), which has become a major cause of end-stage renal disease. According to the International Diabetes Federation, 463 million people worldwide are living with DM in 2019, which will rise to 700 million by 2045. Approximately 20% to 40% of patients with DM progress to DKD. Current therapeutic strategies for DKD are mainly focused on glycemic and hypertensive control, pharmaceuticals treatme
  2022-04-04 · Subject: Fufang Xueshuantong Jiaonang; 复方血栓通胶囊; Fufang Xueshuantong Capsule; Compound Xue Shuan Tong Capsule · open the formula record
• Systematic review registration CRD42022295713 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of TCMIs in patients after PCI : systematic review and network meta-analysis
  Condition or outcome area: Percutaneous coronary interventions (PCIs) are increasingly being performed in the treatment of coronary artery disease. However, some patients under PCI treatment may experience chest pain, acute vessel closure during the periprocedural period, management of the vascular access site and MACE. So, drug therapies especially traditional Chinese medicine injections after percutaneous coronary interventions are important interventions for the secondary prevention of coronary events.
  2022-01-04 · Subject: Dan Shen Zhu She Ye; 丹参注射液; Dan Shen Injection · open the formula record
• Systematic review registration CRD42021258120 Registered protocol, no results here: Review Ongoing
  A systematic review and meta-analysis of Annao pill in patients with post-stroke depression
  Condition or outcome area: Post-stroke depression (PSD) is a common psychiatric sequela, which affects around one-third of stroke patients. Today the majority of PSD patients remain untreated or inadequately treated. Antidepressants (AD) is mainly pharmaceutical treatment for PSD. However, AD is limited by its poor therapeutic effect and increased incidence of adverse events (AEs). Annao pill, a traditional Chinese patent medicine, has been widely used to remit the symptom of post-stroke depression. The need to find evide
  2021-06-29 · Subject: An Nao Wan; 安脑丸; Annao Pill; An Nao Pill · open the formula record
• Systematic review registration CRD42016035584 Registered protocol, no results here: status not recorded
  What are the risks of major cardiovascular events (MACE) from testosterone replacement therapy (TRT)?
  2016-02-19 · Subject: Testosterone; 58-22-0; Testosteron; Androderm; Testim; Homosterone; Virosterone; Testiculosterone; Androlin; Mertestate · open the ingredient record
• Systematic review registration CRD42020200746 Registered protocol, no results here: Review Ongoing
  Efficacy of Intranasal Oxytocin in Food Intake and Craving: A Meta-analysis of clinical trials
  Condition or outcome area: Obesity is a major global health issue, which is associated with not only physical diseases but also negative emotions and perceptions. In addition, patients with eating disorders, especially anorexia nervosa and bulimia nervosa, are preoccupied with psychological conflicts of body weight, which leads to further anxiety, depression, and variety of diverse medical complications. Current approach for the management of obesity, such as initiation and maintenance of a healthy lifestyle, pharmaceutic
  2020-08-28 · Subject: Oxytocin; 50-56-6; Pitocin; Endopituitrina; Ocytocin; Syntocinon; Oxytocinum; Orasthin; Oxystin; alpha-Hypophamine · open the ingredient record
• Systematic review registration CRD42016036586 Registered protocol, no results here: status not recorded
  Magnesium sulfate therapy for acute stroke: a systematic review and meta-analysis of randomised controlled trials
  Condition or outcome area: Stroke is the second major cause of death and the main leading cause of adult disability worldwide. Wherein ischemic stroke accounts for about 80% of all types of stroke. Tissue plasminogen activator (t-PA), the only pharmaceutical treatment approved by a regulatory agency for ischemic stroke, is used in only 2 to 7% of patients with stroke. Mechanical thrombectomy should be used later than thrombolytic agents, after substantial damage has accumulated and they functional outcomes in only 33 to 3
  Subject: Magnesium sulfate; Magnesium Sulfate; 7487-88-9; Magnesium sulphate; Magnesium sulfate anhydrous; MgSO4; Magnesium sulfate (1:1); Magnesiumsulfat; Sal Angalis; Sal De sedlitz · open the ingredient record
• Systematic review registration CRD42020219131 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of colchicine treatment on major cardiac adverse events
  Condition or outcome area: MACE, defined as a composite of cardiovascular death, MI, stroke, or revascularization, as well as atrial fibrillation, unstable angina, deep vein thrombosis, cardiac arrest, all-cause mortality and major AEs (adverse events, included gastrointestinal (GI) symptoms, myalgia, cancer, infection, and pneumonia).
  2020-12-05 · Subject: Colchicine; 64-86-8; Colchisol; Colchicinum; Colchicin; Colchicina; Colchineos; Condylon; Colcin; Colsaloid · open the ingredient record
• Systematic review registration CRD42017067427 Registered protocol, no results here: status not recorded
  The efficacy and safety of anti-inflammatory biologics, disease-modifying anti-rheumatic drugs (DMARDs) and colchicine in osteoarthritis: protocol for a conventional meta-analysis
  Condition or outcome area: Osteoarthritis is the most common joint disorder, and frequently affects the knee, hand, foot, and hip joints. Pain is the most troubling symptom for individuals with osteoarthritis, yet the pharmaceutical treatments recommended by various guidelines provide only small-to-moderate pain relief.
  Subject: Colchicine; 64-86-8; Colchisol; Colchicinum; Colchicin; Colchicina; Colchineos; Condylon; Colcin; Colsaloid · open the ingredient record
• Systematic review registration CRD42016035254 Registered protocol, no results here: Review Ongoing
  Relative efficacy of topical non-steroidal anti-inflammatory drugs and topical capsaicin in osteoarthritis: an individual patient data meta-analysis
  Condition or outcome area: Osteoarthritis is the most common joint disorder, and frequently affects the knee, hand, foot, and hip joints. Pain is the most troubling symptom for individuals with osteoarthritis, yet the pharmaceutical treatments recommended by various guidelines provide only small-to-moderate pain relief.
  2016-03-03 · Subject: Capsaicin; 404-86-4; (E)-Capsaicin; Zostrix; CAPSAICINE; Qutenza; Styptysat; Axsain; trans-Capsaicin; Isodecenoic acid vanillylamide · open the ingredient record
• Systematic review registration CRD42021225844 Registered protocol, no results here: Review Completed published
  Effects and safety of consumption of caffeine in the development of neurocognitive, cardiovascular, lactation disorders and carcinogenesis in children, adults and pregnant women. Systematic review√
  Condition or outcome area: Caffeine is a natural alkaloid and psychoactive drug, which blocks the receptors for adenosine and gamma amino-butyric acid (GABA) in the central nervous system, it is thus the psychoactive drug most consumed worldwide, because it produces cognitive changes- behavioral, cardiovascular, respiratory; for which the pharmaceutical, cosmetic and food industries add it to their products. However, although there are investigations that have reported the appearance of adverse effects, mainly in pregnant
  2021-01-11 · Subject: Caffeine; 58-08-2; Guaranine; 1,3,7-Trimethylxanthine; Methyltheobromine; Theine; Thein; Cafeina; Koffein; Mateina · open the ingredient record
• Systematic review registration CRD42020220956 Registered protocol, no results here: status not recorded
  Effectiveness of orthokeratology combined with 0.01% atropine for Myopia in Asian children and adolescents：A Meta-analysis
  Condition or outcome area: Childhood myopia has become a serious public concern, particularly in East Asia. A recent meta-analysis estimated the prevalence would reach about 69% in children 15 years of age and 80% in those 18 years of age. Increased severity of myopia significantly elevates the risk of developing sight threatening ocular diseases, including myopic maculopathy, glaucoma, cataract, and retinal detachment. To reduce the risk of myopia-related pathologies in later life, a range of potential pharmaceutical and
  Subject: Atropine; dl-Hyoscyamine; 51-55-8; Tropine tropate; Atropen; Atropin; dl-Tropyltropate; Atropinol; Eyesules; Isopto-atropine · open the ingredient record
• Systematic review registration CRD42022309813 Registered protocol, no results here: Review Completed not published
  The effects of vitamin D and/or calcium supplementation and exercise on bone mineral density in adults – a comparative systematic review and meta-analysis
  Condition or outcome area: Osteoporosis is a major global public health problem. The disease is characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and increase in fracture risk. Vitamin D and/or calcium supplementation combined with exercise are considered to be low-threshold and safe non-pharmaceutical treatment strategy for prevention of osteoporosis.
  2022-03-12 · Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · open the ingredient record
• Systematic review registration CRD42022309813 Registered protocol, no results here: Review Completed not published
  The effects of vitamin D and/or calcium supplementation and exercise on bone mineral density in adults – a comparative systematic review and meta-analysis
  Condition or outcome area: Osteoporosis is a major global public health problem. The disease is characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and increase in fracture risk. Vitamin D and/or calcium supplementation combined with exercise are considered to be low-threshold and safe non-pharmaceutical treatment strategy for prevention of osteoporosis.
  2022-03-12 · Subject: Calcium; 7440-70-2; Ca; Elemental calcium; Calcium, elemental; HSDB 273; UNII-SY7Q814VUP; SY7Q814VUP; EINECS 231-179-5; Kalzium · open the ingredient record
• Publication PMID 34575438 Research model: Cell Experiment
  Poly(lactic-co-glycolic acid) Nanoparticles Encapsulating the Prenylated Flavonoid, Xanthohumol, Protect Corneal Epithelial Cells from Dry Eye Disease-Associated Oxidative Stress
  Condition or outcome area: dry eye disease; ocular surface disease
  Pharmaceutics · 2021 · Subject: Xanthohumol; 6754-58-1; 569-83-5; Xantho-flav; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; UNII-T4467YT1NT; (E/Z)-Xanthohumol; T4467YT1NT; (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; CHEBI:66331 · open the ingredient record · DOI 10.3390/pharmaceutics13091362
• Publication PMID 35745829 Research model: Animal & Cell Experiment
  Evaluation of the Cytotoxic, Anti-Inflammatory, and Immunomodulatory Effects of Withaferin A (WA) against Lipopolysaccharide (LPS)-Induced Inflammation in Immune Cells Derived from BALB/c Mice
  Condition or outcome area: inflammation
  Pharmaceutics · 2022 · Subject: Withaferin a; Withaferin A; 5119-48-2; Withaferine A; NSC 273757; WITHAFERIN DERIV JPR, IOWA U. COMPOUND; CHEBI:69120; NSC-101088; NSC101088; L6DO3QW4K5 · open the ingredient record · DOI 10.3390/pharmaceutics14061256
• Publication PMID 34575495 Research model: Others
  Comprehensive Investigation of Stereoselective Food Drug Interaction Potential of Resveratrol on Nine P450 and Six UGT Isoforms in Human Liver Microsomes
  Pharmaceutics · 2021 · Subject: Trans-resveratrol; Resveratrol; resveratrol; 501-36-0; 3,4',5-Trihydroxystilbene; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; 3,5,4'-Trihydroxystilbene; (E)-resveratrol; Resvida; 3,4',5-Stilbenetriol · open the ingredient record · DOI 10.3390/pharmaceutics13091419
• Publication PMID 34202008 Research model: Animal & Cell Experiment
  Comparison of Pharmacokinetics and Anti-Pulmonary Fibrosis-Related Effects of Sulforaphane and Sulforaphane N-acetylcysteine
  Condition or outcome area: fibrosis
  Pharmaceutics · 2021 · Subject: Sulforathane; Sulforaphane; sulforaphane; 4478-93-7; DL-Sulforaphane; 1-Isothiocyanato-4-(methylsulfinyl)butane; D,L-Sulforaphane; Sulforafan; 1-isothiocyanato-4-methylsulfinylbutane; 1-Isothiocyanato-4-(methylsulfinyl)-butane · open the ingredient record · DOI 10.3390/pharmaceutics13070958
• Publication PMID 35056941 Research model: Cell Experiment
  The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model
  Condition or outcome area: pre-diabetic; dyslipidemia; inflammation; hepatic steatosis; liver steatosis; diabetes mellitus; diabetes; fatty liver disturbances
  Pharmaceutics · 2021 · Subject: Silymarin; Silybin; 65666-07-1; Legalon; 84604-20-6; (2R,3R)-3,5,7-trihydroxy-2-[(2R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one; Silibin; 142796-20-1; 36804-17-8; Apihepar · open the ingredient record · DOI 10.3390/pharmaceutics14010045
• Publication PMID 34371773 Research model: Cell Experiment
  Schisandrol A Exhibits Estrogenic Activity via Estrogen Receptor α-Dependent Signaling Pathway in Estrogen Receptor-Positive Breast Cancer Cells
  Condition or outcome area: breast cancer
  Pharmaceutics · 2021 · Subject: Schisandrol a; Schisandrol A; 7432-28-2; (9R,10S)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-9-ol; hexamethoxy(dimethyl)[?]ol; CHEMBL1669433; AKOS015965247; AC-20311; AC-34829; (6R,7S)-1,2,3,10,11,12-Hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulen-6-ol · open the ingredient record · DOI 10.3390/pharmaceutics13071082
• Publication PMID 34575489 Research model: Cell Experiment
  Development of Dextran-Coated Magnetic Nanoparticles Loaded with Protocatechuic Acid for Vascular Inflammation Therapy
  Condition or outcome area: Vascular inflammation; vascular inflammation; atherosclerosis
  Pharmaceutics · 2021 · Subject: Protocatechuic acid; 3,4-Dihydroxybenzoic acid; 3,4-DIHYDROXYBENZOIC ACID; 99-50-3; Protocatehuic acid; 4-Carboxy-1,2-dihydroxybenzene; 4,5-Dihydroxybenzoic acid; Benzoic acid, 3,4-dihydroxy-; protocatechuate; MFCD00002509 · open the ingredient record · DOI 10.3390/pharmaceutics13091414
• Publication PMID 36297636 Research model: Animal & Cell Experiment
  Polydatin Ameliorates High Fructose-Induced Podocyte Oxidative Stress via Suppressing HIF-1α/NOX4 Pathway
  Condition or outcome area: podocyte damage; glomerular podocyte injury
  Pharmaceutics · 2022 · Subject: Polydatin; Piceid; 27208-80-6; 65914-17-2; Trans-Piceid; 3,4,5-Trihydroxystilbene-3-beta-monoglucoside; 3,4,5-Tsg; Resveratrol 3-beta-mono-D-glucoside; Resveratrol 3-O-beta-glucopyranoside; (2S,3R,4S,5S,6R)-2-(3-Hydroxy-5-(4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol · open the ingredient record · DOI 10.3390/pharmaceutics14102202
• Publication PMID 35056946 Research model: Animal Experiment
  Polydatin Alleviates Diabetes-Induced Hyposalivation through Anti-Glycation Activity in db/db Mouse
  Condition or outcome area: Diabetes mellitus; type 2 diabetes; hypofunction of the salivary gland; diabetic complications; salivary gland hypofunction; diabetes mellitus; diabetes-related salivary cell injury; hyposalivation; diabetes
  Pharmaceutics · 2021 · Subject: Polydatin; Piceid; 27208-80-6; 65914-17-2; Trans-Piceid; 3,4,5-Trihydroxystilbene-3-beta-monoglucoside; 3,4,5-Tsg; Resveratrol 3-beta-mono-D-glucoside; Resveratrol 3-O-beta-glucopyranoside; (2S,3R,4S,5S,6R)-2-(3-Hydroxy-5-(4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol · open the ingredient record · DOI 10.3390/pharmaceutics14010051
• Publication PMID 34066937 Research model: Cell Experiment
  Nobiletin Inhibits Inflammatory Reaction in Interleukin-1β-Stimulated Human Periodontal Ligament Cells
  Condition or outcome area: periodontal lesions; periodontal disease
  Pharmaceutics · 2021 · Subject: Nobiletin; 478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; NSC-76751; CCRIS 9012; UNII-D65ILJ7WLY · open the ingredient record · DOI 10.3390/pharmaceutics13050667
• Publication PMID 34834317 Research model: Animal Experiment
  The Use of Menthol in Skin Wound Healing-Anti-Inflammatory Potential, Antioxidant Defense System Stimulation and Increased Epithelialization
  Pharmaceutics · 2021 · Subject: Menthol; dl-Menthol; 1490-04-6; 2-Isopropyl-5-methylcyclohexanol; 15356-70-4; 89-78-1; Cyclohexanol, 5-methyl-2-(1-methylethyl)-; Menthyl alcohol; p-Menthan-3-ol; Mentholum · open the ingredient record · DOI 10.3390/pharmaceutics13111902
• Publication PMID 34201978 Research model: Cell Experiment
  Electrically Triggered Drug Delivery from Novel Electrospun Poly(Lactic Acid)/Graphene Oxide/Quercetin Fibrous Scaffolds for Wound Dressing Applications
  Pharmaceutics · 2021 · Subject: Quercetin; 117-39-5; Sophoretin; Meletin; Quercetine; Xanthaurine; Quercetol; Quertine; Quercitin; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one · open the ingredient record · DOI 10.3390/pharmaceutics13070957
• Publication PMID 32357395 Research model: Animal & Cell Experiment
  Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats
  Condition or outcome area: cervical cancer; breast cancer
  Pharmaceutics · 2020 · Subject: Quercetin; 117-39-5; Sophoretin; Meletin; Quercetine; Xanthaurine; Quercetol; Quertine; Quercitin; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one · open the ingredient record · DOI 10.3390/pharmaceutics12050397
• Publication PMID 36559338 Research model: Cell Experiment
  Effects of Mangiferin on LPS-Induced Inflammation and SARS-CoV-2 Viral Adsorption in Human Lung Cells
  Condition or outcome area: mitochondrial dysfunction; COVID-19 infection
  Pharmaceutics · 2022 · Subject: Mangiferin; 4773-96-0; Chinonin; Alpizarin; Hedysarid; Aphloiol; Chinomin; Alpizarine; UNII-1M84LD0UMD; 1M84LD0UMD · open the ingredient record · DOI 10.3390/pharmaceutics14122845
• Publication PMID 35890318 Research model: Cell Experiment
  Immunomodulatory Effect of Hispolon on LPS-Induced RAW264.7 Cells and Mitogen/Alloantigen-Stimulated Spleen Lymphocytes of Mice
  Condition or outcome area: immune-mediated inflammatory diseases; tumor
  Pharmaceutics · 2022 · Subject: Hispolon; 173933-40-9; HISPOLON(P); (3Z,5E)-6-(3,4-dihydroxyphenyl)-4-hydroxyhexa-3,5-dien-2-one; (3Z,5E)-6-(3,4-dihydroxyphenyl)-4-hydroxy-hexa-3,5-dien-2-one; CHEMBL452722; SCHEMBL15917284; SCHEMBL20978310; CHEBI:212795; DTXSID701045719 · open the ingredient record · DOI 10.3390/pharmaceutics14071423
• Publication PMID 32033492 Research model: Cell Experiment
  Skin Irritation Testing beyond Tissue Viability: Fucoxanthin Effects on Inflammation, Homeostasis, and Metabolism
  Pharmaceutics · 2020 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/pharmaceutics12020136
• Publication PMID 33477262 Research model: Cell Experiment
  Fraxetin Suppresses Cell Proliferation and Induces Apoptosis through Mitochondria Dysfunction in Human Hepatocellular Carcinoma Cell Lines Huh7 and Hep3B
  Condition or outcome area: breast and lung cancer; hepatocellular carcinoma
  Pharmaceutics · 2021 · Subject: Fraxetin; 574-84-5; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one; 7,8-Dihydroxy-6-methoxycoumarin; 7,8-dihydroxy-6-methoxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-6-methoxy-; 7,8-Dihydroxy-6-methoxy-chromen-2-one; 7,8-Dihydroxy-6-methoxy-2-benzopyrone; CD3GD44O3K; CHEMBL54909 · open the ingredient record · DOI 10.3390/pharmaceutics13010112
• Publication PMID 33535454 Research model: Others
  Tetrahydrofurofuranoid Lignans, Eudesmin, Fargesin, Epimagnolin A, Magnolin, and Yangambin Inhibit UDP-Glucuronosyltransferase 1A1 and 1A3 Activities in Human Liver Microsomes
  Pharmaceutics · 2021 · Subject: Eudesmin; Eudesmine; 526-06-7; (-)-Eudesmin; (3R,3aS,6R,6aS)-3,6-bis(3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan; NSC35476; (3R,3aS,6R,6aS)-3,6-bis(3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro(3,4-c)furan; 1H,3H-Furo[3,4-c]furan, 1,4-bis(3,4-dimethoxyphenyl)tetrahydro-,(1R,3aS,4R,6aS)-; SCHEMBL167340; CHEMBL523743 · open the ingredient record · DOI 10.3390/pharmaceutics13020187
• Publication PMID 35745868 Research model: Animal Experiment
  Formulated Curcumin Prevents Paclitaxel-Induced Peripheral Neuropathy through Reduction in Neuroinflammation by Modulation of α7 Nicotinic Acetylcholine Receptors
  Condition or outcome area: burning pain; peripheral neuropathy; Paclitaxel-induced peripheral neuropathy; peripheral neuropathies; mechanical allodynia; solid malignancies
  Pharmaceutics · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/pharmaceutics14061296
• Publication PMID 35056961 Research model: Cell Experiment
  Oxyresveratrol Inhibits TNF-α-Stimulated Cell Proliferation in Human Immortalized Keratinocytes (HaCaT) by Suppressing AKT Activation
  Condition or outcome area: psoriasis; inflammatory disease; psoriatic; Psoriasis
  Pharmaceutics · 2021 · Subject: Cudranin; Oxyresveratrol; 29700-22-9; Hydroxyresveratrol; Tetrahydroxystilbene; (E)-4-(3,5-Dihydroxystyryl)benzene-1,3-diol; trans-oxyresveratrol; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol; 4721-07-7; 1,3-Benzenediol, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]- · open the ingredient record · DOI 10.3390/pharmaceutics14010063
• Publication PMID 35213960 Research model: Cell Experiment
  Green Nanoemulsion Stabilized by In Situ Self-Assembled Natural Oil/Native Cyclodextrin Complexes: An Eco-Friendly Approach for Enhancing Anticancer Activity of Costunolide against Lung Cancer Cells
  Condition or outcome area: malignancy; lung cancer; leukemia; Lung cancer
  Pharmaceutics · 2022 · Subject: Costunolide; 553-21-9; (+)-costunolide; Costunlide; Costunolid; Costus lactone; CHEMBL86416; CHEBI:3900; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one · open the ingredient record · DOI 10.3390/pharmaceutics14020227
• Publication PMID 36015278 Research model: Animal Experiment
  Cordycepin Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats via Modulation of AMPK and AKT Activation
  Condition or outcome area: Benign prostatic hyperplasia; tumor
  Pharmaceutics · 2022 · Subject: Cordycepin; 3'-Deoxyadenosine; 73-03-0; Cordycepine; 9-Cordyceposidoadenine; ADENOSINE, 3'-DEOXY-; 9-(beta-D-3'-Deoxyribofuranosyl)adenine; CCRIS 3233; UNII-GZ8VF4M2J8; EINECS 200-791-4 · open the ingredient record · DOI 10.3390/pharmaceutics14081652
• Publication PMID 36015301 Research model: Cell Experiment
  Cinnamic Acid Attenuates Peripheral and Hypothalamic Inflammation in High-Fat Diet-Induced Obese Mice
  Condition or outcome area: Obesity; obesity; glucose intolerance; dyslipidemia; chronic inflammation; tumor; epididymal fat gain; hepatic and renal toxicity; metabolic disorders
  Pharmaceutics · 2022 · Subject: Cinnamic acid; Cinnamic Acid; TRANS-CINNAMIC ACID; 140-10-3; 621-82-9; 3-Phenylacrylic acid; (E)-Cinnamic acid; trans-3-Phenylacrylic acid; Phenylacrylic acid; Zimtsaeure · open the ingredient record · DOI 10.3390/pharmaceutics14081675
• Publication PMID 35214061 Research model: Cell Experiment
  The Natural Chemotherapeutic Capsaicin Activates AMPK through LKB1 Kinase and TRPV1 Receptors in Prostate Cancer Cells
  Condition or outcome area: Capsaicin-induced; prostate cancer; prostate tumors
  Pharmaceutics · 2022 · Subject: Capsaicin; 404-86-4; (E)-Capsaicin; Zostrix; CAPSAICINE; Qutenza; Styptysat; Axsain; trans-Capsaicin; Isodecenoic acid vanillylamide · open the ingredient record · DOI 10.3390/pharmaceutics14020329
• Publication PMID 34575494 Research model: Cell Experiment
  Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment
  Condition or outcome area: cancers; bladder cancer; Cannabidiol
  Pharmaceutics · 2021 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record · DOI 10.3390/pharmaceutics13091415
• Publication PMID 36559293 Research model: Cell Experiment
  Alpinetin Suppresses Zika Virus-Induced Interleukin-1β Production and Secretion in Human Macrophages
  Condition or outcome area: Zika virus (ZIKV) infection
  Pharmaceutics · 2022 · Subject: Alpinetin; 36052-37-6; (S)-7-Hydroxy-5-methoxy-2-phenylchroman-4-one; (-)-alpinetin; (S)-7-Hydroxy-5-methoxyflavanone; 5-O-Methylpinocembrin; Alpinetin, (S)-; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-5-methoxy-2-phenyl-, (2S)-; (2S)-7-hydroxy-5-methoxy-2-phenyl-2,3-dihydrochromen-4-one; SX3EL59QD8 · open the ingredient record · DOI 10.3390/pharmaceutics14122800
• Publication PMID 33670981 Research model: Animal Experiment
  6-Gingerol, a Bioactive Compound of Ginger Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats by Regulating the Oxidative Stress and Inflammation
  Condition or outcome area: degeneration of pancreatic Langerhans; renal injury; diabetic; hyperlipidaemia; diabetes mellitus; diabetes
  Pharmaceutics · 2021 · Subject: 6-gingerol; Gingerol; gingerol; 23513-14-6; [6]-Gingerol; (6)-Gingerol; (S)-(+)-[6]Gingerol; (S)-(6)-Gingerol; (S)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one; (5S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one · open the ingredient record · DOI 10.3390/pharmaceutics13030317
• Publication PMID 35336037 Research model: Cell Experiment
  3,4-Dihydroxyphenylethanol (DPE or Hydroxytyrosol) Counteracts ERK1/2 and mTOR Activation, Pro-Inflammatory Cytokine Release, Autophagy and Mitophagy Reduction Mediated by Benzo[a]pyrene in Primary Human Colonic Epithelial Cells
  Condition or outcome area: cancers; colon carcinogenesis; inflammatory bowel disease; colon cancer; cancer
  Pharmaceutics · 2022 · Subject: 3,4-dihydroxyphenethyl alcohol; Hydroxytyrosol; 10597-60-1; 3,4-Dihydroxyphenylethanol; 4-(2-hydroxyethyl)benzene-1,2-diol; 2-(3,4-Dihydroxyphenyl)ethanol; dopet; 3-Hydroxytyrosol; 1,2-Benzenediol, 4-(2-hydroxyethyl)-; 3,4-Dihydroxyphenethylalcohol · open the ingredient record · DOI 10.3390/pharmaceutics14030663
• Publication PMID 35214100 Research model: Animal Experiment
  Gallic Acid as a Non-Selective Inhibitor of α/β-Hydrolase Fold Enzymes Involved in the Inflammatory Process: The Two Sides of the Same Coin
  Condition or outcome area: Pharmacological edema; myotoxicity
  Pharmaceutics · 2022 · Subject: Gallic acid; Gallic Acid; 149-91-7; 3,4,5-Trihydroxybenzoic acid; gallate; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.; Kyselina gallova; Pyrogallol-5-carboxylic acid; GALOP · open the ingredient record · DOI 10.3390/pharmaceutics14020368
• Publication PMID 34834209 Research model: Animal & Cell Experiment
  Regulation of ROS-Dependent JNK Pathway by 2'-Hydroxycinnamaldehyde Inducing Apoptosis in Human Promyelocytic HL-60 Leukemia Cells
  Condition or outcome area: tumor; HL-60 leukemia; leukemia; promyelocytic leukemia
  Pharmaceutics · 2021 · Subject: 2'-hydroxycinnamaldehyde; 3-(2-Hydroxyphenyl)prop-2-enal; 3-(2-hydroxyphenyl)prop-2-enal; o-Hydroxy-trans-cinnamaldehyde; 2-Propenal, 3-(2-hydroxyphenyl)-, (E)-; (2E)-3-(2-Hydroxyphenyl)-2-propenal; DTXSID301313734; AKOS030230060 · open the ingredient record · DOI 10.3390/pharmaceutics13111794